- Trials with a EudraCT protocol (14)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (4)
14 result(s) found for: Depressants.
Displaying page 1 of 1.
EudraCT Number: 2009-012428-10 | Sponsor Protocol Number: MBCT2009 | Start Date*: 2009-11-06 |
Sponsor Name:University of Exeter | ||
Full Title: Preventing depression relapse / recurrence in NHS settings through mindfulness-based cognitive therapy (MBCT). | ||
Medical condition: Recurrent depression. Patients who have experienced 3 or more episodes of depression and are already taking anti-depressants will be invited to take part in this study. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2004-004249-16 | Sponsor Protocol Number: F02207GE204 | Start Date*: 2005-02-02 |
Sponsor Name:PIERRE FABRE MEDICAMENT | ||
Full Title: THE EFFECT OF MILNACIPRAN 100MG BID ON SENSITIVITY TO STIMULUS-EVOKED PAIN IN PATIENTS WITH FIBROMYALGIA: A FMRI NEUROIMAGING STUDY | ||
Medical condition: Fibromyalgia is a chronic disorder characterized by widespread musculoskeletal pain, widespread tenderness and fatigue. The disorder is well defined in the USA, where the current diagnosis of FMS i... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Completed) SE (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-003739-32 | Sponsor Protocol Number: 2PX-PHN-01 | Start Date*: 2005-12-23 |
Sponsor Name:Santosolve A/S | ||
Full Title: A double-blind, placebo-controlled, enriched enrolment, randomised withdrawal study to evaluate the efficacy and safety of 2PX in patients with neuropathic pain due to post-herpetic neuralgia | ||
Medical condition: Patients suffering from pain due to post-herpetic neuralgia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2009-015728-27 | Sponsor Protocol Number: AH-IBS-005 | Start Date*: 2009-11-13 |
Sponsor Name:Alimentary Health Ltd | ||
Full Title: A Double Blind, Randomised, placebo-contoled Trial to establish teh safety and efficacy of a probiotic in subjects with Irritable Bowel Syndrome | ||
Medical condition: Irritable bowel Syndrome | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-003137-40 | Sponsor Protocol Number: F02207GE302 | Start Date*: 2015-09-28 |
Sponsor Name:Pierre Fabre Medicament | ||
Full Title: A European Phase III, Multicentre, Double-blind, Randomised, Placebo-Controlled Monotherapy Study of Milnacipran for the Treatment of the Fibromyalgia Syndrome. | ||
Medical condition: Fibromyalgia, also known as FMS, is a common systemic rheumatologic disorder estimated to affect 2 to 4% of the population Fibromyalgia is associated with a reduced threshold for pain, generally i... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) FI (Completed) SE (Completed) ES (Completed) PT (Completed) DE (Completed) GB (Completed) CZ (Completed) IT (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-001230-41 | Sponsor Protocol Number: F02207GE304 | Start Date*: 2006-08-17 | |||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT | |||||||||||||
Full Title: A EUROPEAN PHASE III, MULTICENTRE, DOUBLE-BLIND, RANDOMISED, MONOTHERAPY, 12-MONTH STUDY OF MILNACIPRAN FOR THE TREATMENT OF THE FIBROMYALGIA SYNDROME | |||||||||||||
Medical condition: Fibromyalgia syndrome (FMS) is a common systemic rheumatologic disorder estimated to affect 2 to 4% of the population. Fibromyalgia is associated with a reduced threshold for pain, generally identi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) DE (Completed) GB (Prematurely Ended) DK (Prematurely Ended) PT (Completed) CZ (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015165-31 | Sponsor Protocol Number: EME-08/43/39 | Start Date*: 2010-07-16 |
Sponsor Name:Northumberland, Tyne and Wear NHS Foundation Trust | ||
Full Title: Antiglucocorticoid augmentation of antiDepressants in Depression: a double-blind, randomised, placebo-controlled, parallel-group trial | ||
Medical condition: depression | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-000143-12 | Sponsor Protocol Number: ORBIS-DE-UNIBO001 | Start Date*: 2019-07-25 | |||||||||||
Sponsor Name:ALMA MATER STUDIORUM UNIVERSITà DI BOLOGNA | |||||||||||||
Full Title: OXYTOCIN RESEARCH FOR BEHAVIORAL IMPAIRMENT SYMPTOMS IN DEMENTIA: Potential clinical efficacy of intranasal oxytocin in the treatment of frontotemporal dementia. A randomized, double-blind, placebo... | |||||||||||||
Medical condition: Frontotemporal dementia (bvFTD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001832-23 | Sponsor Protocol Number: NEU_CH_7911 | Start Date*: 2013-10-23 | |||||||||||
Sponsor Name:Neurim Pharmaceuticals (1991) Ltd. | |||||||||||||
Full Title: A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF CIRCADIN® TO ALLEVIATE SLEEP DISTURBANCES IN CHILDREN WITH NEURODEVELOPMENTAL DISABILITIES | |||||||||||||
Medical condition: SLEEP DISTURBANCES IN CHILDREN WITH NEURODEVELOPMENTAL DISABILITIES | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA FI (Completed) GB (Completed) NL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002143-25 | Sponsor Protocol Number: M06-873 | Start Date*: 2008-11-11 | ||||||||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | ||||||||||||||||||
Full Title: A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia. | ||||||||||||||||||
Medical condition: Relapsed or Refractory Chronic Lymphocytic Leukemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001176-15 | Sponsor Protocol Number: BIA-91067-405 | Start Date*: 2021-05-07 | |||||||||||
Sponsor Name:Bial - Portela & Ca, S.A. | |||||||||||||
Full Title: Open-label, single-arm, pilot study to evaluate the effect of opicapone 50 mg on Parkinson’s disease patients with end-of-dose motor fluctuations and associated sleep disorders. | |||||||||||||
Medical condition: Parkinson's disease patients with wearing-off motor fluctuations and associated sleep disorders. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003298-28 | Sponsor Protocol Number: M06-822 | Start Date*: 2007-05-23 | |||||||||||
Sponsor Name:Abbott Laboratories Limited (Queenborough, Kent, ME11 5EL, England) | |||||||||||||
Full Title: A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Small Cell Lung Cancer (SCLC) or other non-hematological malignancies. | |||||||||||||
Medical condition: Small cell lung carcinoma (SCLC) (North America or UK) and other non-hematological malignancies (North America only). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001521-16 | Sponsor Protocol Number: 1VIT14037 | Start Date*: 2015-07-15 | |||||||||||
Sponsor Name:Luitpold Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Double-Blinded, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) in the Treatment of Restless Legs Syndrome (RLS) | |||||||||||||
Medical condition: Restless Leg Syndrome (RLS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) PL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011743-39 | Sponsor Protocol Number: CAFQ056A2207 | Start Date*: 2009-09-18 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration Proof of Concept study in patients with Huntington's disease to assess the efficacy, safet... | |||||||||||||
Medical condition: Huntington's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
